Mentions
Extended reach
Total likes
Video views
AI synopsis
In these discussions, participants often cite the substantial mortality reduction associated with empagliflozin, such as a 32% decrease in death from cardiovascular causes and a 15% reduction in all-cause mortality. Phrases like 'paradigm shifting' and 'setting the bar for new diabetes drugs' reflect the excitement and serious consideration these findings demand. The tone is predominantly optimistic, with a mix of healthy skepticism regarding study funding, showing a deep engagement with the material by discussing both potential benefits and complications.
Most discussions show a broad support for the conclusions of the publication, with some nuanced skepticism regarding the funding sources.
The discussions indicate high curiosity about empagliflozin and its implications for cardiovascular health and diabetes management.
Participants often reference specific studies, highlight key statistics, and discuss clinical implications, indicating a moderate level of engagement.
Many participants perceive the findings as highly significant, particularly in how they may influence future treatment protocols.
مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في منع الجلطات توجد عدة ادوية منها جارديانس متوفر في #وصفتي وجدت دراسة empa reg انه يقلل وفيات القلب بنسبة ٣٨٪وجلطات القلب١٣٪ https://t.co/TC5nV7J68s https://t.co/AjBinTTySF
If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.co/CpJfIdLO9c
Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety trial and actually showed benefit SGLT2i now considered the statins of the 21st century Remarkable Braunwald is a #flozinator https://t.co/E3lGFseGHc https://t.co/6xTbRHiMfD
I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https://t.co/osz618oJB0 ) In this study SGLT2i reduced mortality of patients with Type 2 Diabetes. But look closely. The drug was ineffective in patients younger than https://t.co/YpilwMyNiH https://t.co/SLBLIbFMR3
2015: EMPA-REG surprise! The trial was designed to test empagliflozin non-inferiority for CV outcomes in pts with T2DM and high CV risk. Result: empagliflozin was superior to placebo and reduced several MACE, including death from any cause. https://t.co/6VIrn3NksE 9/20
"It's almost embarrassing to be this desirable"
Ryker Black reveals findings from a double-blind trial that identifies a revolutionary anti-aging pill, influencing aging processes significantly. The study highlights empagliflozin's positive impact on cardiovascular…
Empagliflozin, a type 2 diabetes medication, reduces cardiovascular deaths and overall mortality in high-risk patients. This video explores the results of recent studies highlighting its effectiveness compared to…
This video discusses the treatment of congestive heart failure in patients with chronic kidney disease. It also addresses an erratum regarding blood pressure terminology at minute 08:33 of the Spanish version. For more…
Huge improvements in treatments for type 2 diabetes are outlined in recent diabetes guidelines. This video discusses the effectiveness of canagliflozin in significantly reducing major cardiovascular events and…
Discover nine vegetables like kale and sauerkraut that help manage blood sugar, boost insulin sensitivity, and prevent complications. Backed by science, these vegetables can become your health-boosting kitchen staples.
@MichaelEvanson1 @_APWK_ This was an industry-funded RCT. Because it was pharma-funded, does it automatically invalidate the results? I agree it should make us more skeptical, but disagree that it automatically invalidates results. https://t.co/PYjXWEG2oI
RT @DrDerekConnolly: @ncurzen That’s why our secondary prevention clinic is so important Nick I’m constantly prescribing evidence based th…
RT @DrDerekConnolly: @ncurzen That’s why our secondary prevention clinic is so important Nick I’m constantly prescribing evidence based th…
RT @DrDerekConnolly: @ncurzen That’s why our secondary prevention clinic is so important Nick I’m constantly prescribing evidence based th…
RT @DrDerekConnolly: @ncurzen That’s why our secondary prevention clinic is so important Nick I’m constantly prescribing evidence based th…
@ncurzen That’s why our secondary prevention clinic is so important Nick I’m constantly prescribing evidence based therapies for patients with diabetes. Everyone who made entry criteria for the SGLT2i trials receives one 32% ⬇️ in death @vinoda_sharma https://t.co/r9NwmyMXvV
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
RT @SsJankauskas: I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https:…
I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https://t.co/osz618oJB0 ) In this study SGLT2i reduced mortality of patients with Type 2 Diabetes. But look closely. The drug was ineffective in patients younger than https://t.co/YpilwMyNiH https://t.co/SLBLIbFMR3
I’ll bet the first anti-aging drug will be an SGLT2 inhibitor. 1️⃣ Look at results of the EMPA-REG OUTCOME trial (https://t.co/osz618oJB0 ) In this study SGLT2i reduced mortality of patients with Type 2 Diabetes. But look closely. The drug was ineffective in patients younger than https://t.co/pAO5AEktp9 https://t.co/SLBLIbFMR3
RT @EndoDialogues: 2015: EMPA-REG surprise! The trial aimed to test the non-inferiority of empagliflozin for CV outcomes in pts with T2D…
2015: EMPA-REG surprise! The trial aimed to test the non-inferiority of empagliflozin for CV outcomes in pts with T2DM and high CV risk. Result: empagliflozin was superior to placebo and reduced several MACE, including death from any cause. https://t.co/6VIrn3NksE
RT @K212462681: SGLT2阻害薬（飢餓状態模倣）で寿命伸びる系の話はメタボ炎症予防でよく知られていて栄養指導でも話題に上る。 SGLT2阻害によりAMPK 活性化剤のAICAR が増加し老化細胞除去効果を発揮。AMPKは、肥満に伴って増加したPD-L1⁺老化細胞…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
SGLT2阻害薬（飢餓状態模倣）で寿命伸びる系の話はメタボ炎症予防でよく知られていて栄養指導でも話題に上る。 SGLT2阻害によりAMPK 活性化剤のAICAR が増加し老化細胞除去効果を発揮。AMPKは、肥満に伴って増加したPD-L1⁺老化細胞（Sero -Anergyに関与）も除去する。 https://t.co/W72lRR40tw https://t.co/i9sj93v3Ex
RT @accpcardprn: "It's almost embarrassing to be this desirable"
RT @accpcardprn: "It's almost embarrassing to be this desirable"
RT @accpcardprn: "It's almost embarrassing to be this desirable"
RT @accpcardprn: "It's almost embarrassing to be this desirable"
RT @accpcardprn: "It's almost embarrassing to be this desirable"
"It's almost embarrassing to be this desirable"
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @AAlMohammad87: The strong onset of #SGLT2i story in #CV medicine was in 2015 with #EMPA_REG trial @NEJM @BSHeartFailure @markcpetrie20…
RT @AAlMohammad87: The strong onset of #SGLT2i story in #CV medicine was in 2015 with #EMPA_REG trial @NEJM @BSHeartFailure @markcpetrie20…
The strong onset of #SGLT2i story in #CV medicine was in 2015 with #EMPA_REG trial @NEJM @BSHeartFailure @markcpetrie20 #CardioTwitter https://t.co/jIdFDcyvls
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes — NEJM https://t.co/C5Onu04RNZ
@Fahad90172146 بناء على دراسات علمية اهمها دراسة تدعى empa reg https://t.co/TC5nV80Hx2
RT @Eddie_Cliff: @NicoGagelmann @nihardesai7 @RahulBanerjeeMD @HadidiSamer @tomam04 @Dr_AmerZeidan @gulderenesra I can’t go past EMPA REG -…
RT @Eddie_Cliff: @NicoGagelmann @nihardesai7 @RahulBanerjeeMD @HadidiSamer @tomam04 @Dr_AmerZeidan @gulderenesra I can’t go past EMPA REG -…
@NicoGagelmann @nihardesai7 @RahulBanerjeeMD @HadidiSamer @tomam04 @Dr_AmerZeidan @gulderenesra I can’t go past EMPA REG - paradigm shifting not only in demonstrating the utility of SGLT2is but also in setting the bar for new diabetes & metabolism drugs as mortality / MACE not just HbA1c (and yes, I used to want to do endo!) https://t.co/cgBsUfoLxw https://t.co/KUA5p9ym20
EMPA-REG OUTCOME Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | NEJM https://t.co/5bO5alnX8O
@Pharmaheretic @geochurch 15% reduction in all-cause mortality, driven by CV. https://t.co/ieTBb0LmcQ 32% reduction in death from any cause: https://t.co/uj8Khq6dNw
@tolquen @DocTotoscope c'est sur le total set, parce que c'était ce qui était écrit dans le protocole comme analyse principale et ça, ça n'a pas été modifié. Ca aurait posé plus problème l'analyse ppale était sur chaque sous groupe et que l'total set ait été un critère 2ndr . https://t.co/kcAukiBHUd
RT @cardiomet_CE: 8) The first suggestions that #SGLT2i could substantially slow progression of #CKD in people with #T2D appeared in 2015 f…
RT @cardiomet_CE: 8) The first suggestions that #SGLT2i could substantially slow progression of #CKD in people with #T2D appeared in 2015 f…
8) The first suggestions that #SGLT2i could substantially slow progression of #CKD in people with #T2D appeared in 2015 from the seminal EMPA-REG OUTCOME trial of #empagliflozin. See
RT @ckd_ce: 8) The first suggestions that #SGLT2i could substantially slow progression of #CKD in people with #T2D appeared in 2015 from th…
8) The first suggestions that #SGLT2i could substantially slow progression of #CKD in people with #T2D appeared in 2015 from the seminal EMPA-REG OUTCOME trial of #empagliflozin. See
RT @mendesthiagob: 2015: EMPA-REG surprise! The trial was designed to test empagliflozin non-inferiority for CV outcomes in pts with T2DM…
2015: EMPA-REG surprise! The trial was designed to test empagliflozin non-inferiority for CV outcomes in pts with T2DM and high CV risk. Result: empagliflozin was superior to placebo and reduced several MACE, including death from any cause. https://t.co/6VIrn3NksE 9/20
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes — NEJM https://t.co/C5Onu04RNZ
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Read more here: https://t.co/ecTXb4nCb1 @ChristophWanne4 @woerle_hans @durocherlab @Boehringer @Yale @NEJM #science #medicine #health #research https://t.co/wLT9RhdeGl
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
RT @drjoharji1: مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في من…
مريض سكري + جلطات قلبية او دماغية او نقص تروية في الاطراف PAD مهم خطته العلاجية تكون محتوية على دواء له ميزة اضافية في منع الجلطات توجد عدة ادوية منها جارديانس متوفر في #وصفتي وجدت دراسة empa reg انه يقلل وفيات القلب بنسبة ٣٨٪وجلطات القلب١٣٪ https://t.co/TC5nV7J68s https://t.co/AjBinTTySF
@djc795 @DavidLBrownMD @kaulcsmc @VictorDayan1 @gbiondizoccai @MDPIOpenAccess I think SGLT2 should also be included. EMPA-REG RCT https://t.co/b3O7sFVmFi
@usambcuba @TheEatRightMonk @aga_pallavi @doc_hormone @parthaskar @NEJM This is some obscure journal . Not @NEJM
24b) Other #DPP4i, #basal #insulin, and α-GI are neutral but and @GLP1 RAs have modest benefit from meta-analysis. #SGLT2i show consistent and robust benefits. Consider
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes — NEJM https://t.co/C5Onu04RNZ
#SGLT2i #Empagliflozin The sage started more than 6 years ago. #DT2 #CKD #HF https://t.co/ewCFhmhJFi
RT @mendesthiagob: The year is 2015 Empagliflozin, a SGLT2i, is the first of the class to show important benefits beyond glucose control:…
RT @mendesthiagob: The year is 2015 Empagliflozin, a SGLT2i, is the first of the class to show important benefits beyond glucose control:…
The year is 2015 Empagliflozin, a SGLT2i, is the first of the class to show important benefits beyond glucose control: ⬇️ HF admission, ⬇️ death from cardiovascular cause and ⬇️ death from any cause in pts with T2D and ⬆️ CV risk EMPA-REG https://t.co/iQKjxE69UN (6/13)
@FrogHarmless @Tom_Babington1 @Nickle1011 @OlivePufa EMPAREG-OUTCOME https://t.co/emu8124Ki5
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
RT @Nephro_Sparks: Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety t…
Dr. Braunwald points out the the EMPA-REG trial was one of the most impactful clinical trials performed. Was a safety trial and actually showed benefit SGLT2i now considered the statins of the 21st century Remarkable Braunwald is a #flozinator https://t.co/E3lGFseGHc https://t.co/6xTbRHiMfD
32) Want a
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes — NEJM https://t.co/C5Onu04RNZ
EMPA-REG was the first trial after 2008 FDA guidance to be converted from noninferiority to superiority as it showed more than safety, it showed benefits! What a landmark! -->35% reduction in HF hospital admissions. https://t.co/iQKjxE69UN
RT @cardiomet_CE: 11) In the 4 initial CV outcomes trials, #CV death was subject to the most heterogeneity, and was most evident in EMPA-RE…
11) In the 4 initial CV outcomes trials, #CV death was subject to the most heterogeneity, and was most evident in EMPA-REG OUTCOME (10.1056/NEJMoa1504720). Less is known about the exact modes of death that #SGLT2i protect against.
EMPA-REG: Empagliflozin (SGLT-2I) was associated with lower all-cause and CV death and hospitalizations for HF among patients with type 2 diabetes. Genital infections were higher with Empagliflozin. #UMKCRCT https://t.co/6wUCEQZG9T
Since then, RCTs dedicated to assessing CVD outcomes in type 2 diabetes treatment were designed for each new drug. Empagliflozin was the first drug to show not only it was safe for CVD outcomes but protective. https://t.co/iQKjxE69UN
RT @jsenior64: ISGLT-2 y desenlaces cardiovasculares. El que empezó todo. https://t.co/JMVQIySdqK
RT @jsenior64: ISGLT-2 y desenlaces cardiovasculares. El que empezó todo. https://t.co/JMVQIySdqK
RT @jsenior64: ISGLT-2 y desenlaces cardiovasculares. El que empezó todo. https://t.co/JMVQIySdqK
ISGLT-2 y desenlaces cardiovasculares. El que empezó todo. https://t.co/JMVQIySdqK
2015: Esse ano teve muitos trabalhos relevantes, mas optei por escolher o EMPAREG. Ele trouxe o primeiro antidiabético oral reduzindo mortalidade CV de modo significativo e abriu portas para todos os usos que temos hoje dos iSGLT-2. Ref: https://t.co/cuoO0pJ09A
The correct answer is D. Empagliflozin slows progression of CKD (Creedence Trial) and decreases HF Mort. (Empa-Reg). Weirdly enough Dapagliflozin even decreases HF mortality in those without DM (Dapa-HF)! https://t.co/uQgWHBCtOK https://t.co/OXfmH0xdNX https://t.co/ejiDl9xakh https://t.co/kOM3bZIjde
@drshafikuchay @AmarPut @kamleshkhunti @AbdTahrani @SABOURETCardio @DrMarthaGulati @GiuseppeGalati_ I very much use them [appropriately] on a daily basis and will use them more as the SmPC indications, @NICEComms and @escardio guidance changes so far [since EMPA-REG] I have had no issues https://t.co/ulqAzvBv49 https://t.co/4QQ5GVcCmC
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
RT @DiscoStew66: If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.c…
If cardiovascular disease can be REDUCED whilst INCREASING LDL, the Diet-Heart Hypothesis has been falsified. https://t.co/CpJfIdLO9c
“Empagliflozin has been associated with an increase in levels of both low-density lipoprotein (LDL)and high-density lipoprotein (HDL) cholesterol. The most common side effects of empagliflozin are urinary tract infection and genital infection”
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | NEJM https://t.co/lhAj4kBfXL
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | NEJM https://t.co/or2Y2D15xu
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://t.co/l58AvoFo3b via @YouTube @mjack2050
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes—cited by Dr. Joel Topf, MD, FACP, St. Clair University @kidney_boy #KidneyCon “It actually saved lives.” https://t.co/Hw6gIuLBqq
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | NEJM https://t.co/1u4QzHVEQQ
#VisualAbstract for EMPA-REG. First take, happy to hear feedback and make changes. http://www.nejm.org/doi/full/10.1056/NEJMoa1504720#t=article
First time we have seen a reduction in mortality with oral hypoglycemic? http://www.nejm.org/doi/full/10.1056/NEJMoa1504720?query=featured_home#abstract
دج
D
MM
S
ED
AP
KM
J
W
VW
HT
PC
B
E
VD
PJ
MM
JG
R
DW
HY
SN
M
OS
七
SA
Z
BB
SF
KP
R
ف
BA
C
AD
AM
DM
NG
DP
EC
EZ
MH
DA
AM
PF
CM
D
CC
MT
S
ج
S
سا
MA
با
FA
JA
KQ
DH
Ŧ
SA
HH
NF
RM
DE
S
D
HG
M
AF
AJ
SA
LF
PT
BH
MR
EN
JR
JR
CC
DM
NK
WF
HH
AR
L
YU
JS
S
DD
GP
JP
T
LS
P
TC
AC
B
CS
PM
ER
PD
HA
دا
KL
DW
HL
A
JE
L
M
L
VE
BD
YM